<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7026011/results/search/disease/results.xml">
  <result pre="Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus" exact="Infection" post="ÁlvarezDiana M.1CastilloEstefanía1DuarteLuisa F.1ArriagadaJosé1CorralesNicolás1FaríasMónica A.1HenríquezAdolfo2Agurto-MuñozCristian23GonzálezPablo A.1*[], 1Millennium Institute on Immunology"/>
  <result pre="Reviewed by: David Leib, Dartmouth College, United States; Guangdi Li," exact="Central" post="South University, China *Correspondence: Pablo A. González, pagonzalez@bio.puc.cl This"/>
  <result pre="does not comply with these terms. Abstract Herpes simplex viruses" exact="type 1" post="(HSV-1) and type 2 (HSV-2) are highly prevalent within"/>
  <result pre="these terms. Abstract Herpes simplex viruses type 1 (HSV-1) and" exact="type 2" post="(HSV-2) are highly prevalent within the human population and"/>
  <result pre="prevalent within the human population and are characterized by lifelong" exact="infections" post="and sporadic recurrences due to latent neuron infection. Upon"/>
  <result pre="others through mucosae body fluids. Although, HSVs can produce severe" exact="disease" post="in humans, such as life-threatening encephalitis and blindness, the"/>
  <result pre="HSVs can produce severe disease in humans, such as life-threatening" exact="encephalitis" post="and blindness, the most common symptoms are skin and"/>
  <result pre="antivirals that can reduce the severity and duration of these" exact="cutaneous" post="manifestations would certainly be welcome. Here, we review currently"/>
  <result pre="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Herpes simplex virus" exact="type 1" post="(HSV-1) and herpes simplex virus type 2 virus (HSV-2)"/>
  <result pre="page-count: word-count: Introduction Herpes simplex virus type 1 (HSV-1) and" exact="herpes" post="simplex virus type 2 virus (HSV-2) are viruses belonging"/>
  <result pre="Herpes simplex virus type 1 (HSV-1) and herpes simplex virus" exact="type 2" post="virus (HSV-2) are viruses belonging to the Herpesviridae family,"/>
  <result pre="and HSV-2 belong to the same family and subfamily than" exact="varicella" post="zoster virus (VZV), yet VZV belongs to the Varicellovirus"/>
  <result pre="HSV-2 belong to the same family and subfamily than varicella" exact="zoster" post="virus (VZV), yet VZV belongs to the Varicellovirus genus"/>
  <result pre="HSV-1 and HSV-2 are highly prevalent in humans, with global" exact="infections" post="ranging 70 and 10% of the world population, respectively"/>
  <result pre="Health Organization, Regional Estimates1. HSV-1 and HSV-2 can cause severe" exact="disease" post="in immunocompetent adults and newborns, such as life-threatening encephalitis"/>
  <result pre="severe disease in immunocompetent adults and newborns, such as life-threatening" exact="encephalitis" post="with sequelae, despite antiviral treatment (Whitley et al., 2007;"/>
  <result pre="Handel et al., 2011). These viruses can also produce eye" exact="infections" post="leading to visual impairment: currently, HSV-1 is the main"/>
  <result pre="2011). These viruses can also produce eye infections leading to" exact="visual" post="impairment: currently, HSV-1 is the main cause of infectious"/>
  <result pre="to visual impairment: currently, HSV-1 is the main cause of" exact="infectious" post="blindness in developed countries (Farooq and Shukla, 2012). However,"/>
  <result pre="visual impairment: currently, HSV-1 is the main cause of infectious" exact="blindness" post="in developed countries (Farooq and Shukla, 2012). However, the"/>
  <result pre="the most common clinical manifestations associated to HSV-1 and HSV-2" exact="infections" post="are herpes labialis and herpes genitalis (Lafferty et al.,"/>
  <result pre="common clinical manifestations associated to HSV-1 and HSV-2 infections are" exact="herpes" post="labialis and herpes genitalis (Lafferty et al., 1987; Mertz"/>
  <result pre="associated to HSV-1 and HSV-2 infections are herpes labialis and" exact="herpes" post="genitalis (Lafferty et al., 1987; Mertz et al., 1998;"/>
  <result pre="into crusts and may last up to 14 days during" exact="primary" post="infections and approximately 10 days during recurrences if no"/>
  <result pre="crusts and may last up to 14 days during primary" exact="infections" post="and approximately 10 days during recurrences if no treatment"/>
  <result pre="Schwartz, 2007). The lesions contain high amounts of virions and" exact="infiltrating" post="leukocytes and may be painful with a burning sensation,"/>
  <result pre="20–50% and 80–90% for HSV-1 and HSV-2 infections, respectively after" exact="primary" post="infection (Mertz et al., 1992; Benedetti et al., 1994;"/>
  <result pre="and 80–90% for HSV-1 and HSV-2 infections, respectively after primary" exact="infection" post="(Mertz et al., 1992; Benedetti et al., 1994; Cowan"/>
  <result pre="is important to note that these persons will nevertheless shed" exact="infectious" post="viral particles from the mucosae, which could infect other"/>
  <result pre="important to note that these persons will nevertheless shed infectious" exact="viral" post="particles from the mucosae, which could infect other individuals"/>
  <result pre="one-third of the persons that have had clinical symptoms during" exact="primary" post="infection show frequent reactivations, which occur on average six"/>
  <result pre="of the persons that have had clinical symptoms during primary" exact="infection" post="show frequent reactivations, which occur on average six times"/>
  <result pre="10–25% of the individuals that are infected with HSV manifest" exact="disease" post="symptoms, particularly skin lesions in various forms (herpes labialis,"/>
  <result pre="disease symptoms, particularly skin lesions in various forms (herpes labialis," exact="herpes" post="genitalis, eczema herpeticum, zosteriforme herpes, etc.) (Mertz et al.,"/>
  <result pre="particularly skin lesions in various forms (herpes labialis, herpes genitalis," exact="eczema" post="herpeticum, zosteriforme herpes, etc.) (Mertz et al., 1992; Cowan"/>
  <result pre="HSV-2, respectively. This extremely high percentage of individuals affected by" exact="symptomatic" post="HSV infection is non-negligible and undoubtedly encompasses a significant"/>
  <result pre="This extremely high percentage of individuals affected by symptomatic HSV" exact="infection" post="is non-negligible and undoubtedly encompasses a significant number of"/>
  <result pre="others (Perna et al., 1987; Rand et al., 1990). Upon" exact="viral" post="reactivation, virions travel in a retrograde manner from the"/>
  <result pre="or the dorsal root ganglia (genital-associated infection), to sites neighboring" exact="epithelial" post="cells and fibroblasts, nearby the original site of infection,"/>
  <result pre="new lesions that will repeat the process of additional neuron" exact="infection" post="(Stevens and Cook, 1971; Lafferty et al., 1987; Benedetti"/>
  <result pre="1994). Given this scenario, it seems important to block neuron" exact="infection" post="by HSV-1 and HSV-2 during primary infection or to"/>
  <result pre="important to block neuron infection by HSV-1 and HSV-2 during" exact="primary" post="infection or to treat neurons in such a way"/>
  <result pre="to block neuron infection by HSV-1 and HSV-2 during primary" exact="infection" post="or to treat neurons in such a way that"/>
  <result pre="other hand, approximately 3.5–10% of immunosuppressed individuals (e.g., transplanted persons," exact="HIV-positive" post="individuals, those undergoing pharmacological treatments to depress the immune"/>
  <result pre="such as acyclovir-resistant isolates may also occur, yet at a" exact="lower" post="frequency (approximately 1% of cases) (Bacon et al., 2002;"/>
  <result pre="first nucleoside analog drugs approved to control HSV-1 and HSV-2" exact="infection" post="(Hassan et al., 2015). Additionally, many plants used in"/>
  <result pre="that have emerged in the last 20 years to treat" exact="herpes" post="simplex viruses. Current Drugs Used Against HSV-1 and HSV-2"/>
  <result pre="acyclovir (ACV), penciclovir, and famciclovir, which inhibit HSV-1 and HSV-2" exact="infection" post="by interfering with the viral DNA polymerase and hence,"/>
  <result pre="which inhibit HSV-1 and HSV-2 infection by interfering with the" exact="viral" post="DNA polymerase and hence, viral genome replication (Kukhanova et"/>
  <result pre="infection by interfering with the viral DNA polymerase and hence," exact="viral" post="genome replication (Kukhanova et al., 2014). These drugs are"/>
  <result pre="drugs, which are described in more detail below, help reduce" exact="disease" post="and minimize potential severe damage, as well as to"/>
  <result pre="onto other individuals, most of these compounds only modestly reduce" exact="cutaneous" post="manifestations (lesions) caused by herpes simplex viruses, particularly when"/>
  <result pre="these compounds only modestly reduce cutaneous manifestations (lesions) caused by" exact="herpes" post="simplex viruses, particularly when used in the form of"/>
  <result pre="Numerous antivirals approved for the treatment of HSV-1 and HSV-2" exact="infections" post="are acyclic nucleoside and nucleotide analogs that interfere with"/>
  <result pre="nucleoside and nucleotide analogs that interfere with the elongation of" exact="viral" post="genome during replication, which is carried out by the"/>
  <result pre="viral genome during replication, which is carried out by the" exact="viral" post="DNA polymerase (UL30). Acyclovir (ACV) is an acyclic guanosine"/>
  <result pre="its antiviral activity. This process is carried out by the" exact="viral" post="thymidine kinase (TK, UL23 gene), which catalyzes acyclovir into"/>
  <result pre="in its triphosphate form, acyclovir becomes a substrate for the" exact="viral" post="DNA polymerase interfering with DNA synthesis (Reusser, 1996; De"/>
  <result pre="De Clercq, 2013). Importantly, inhibition of the synthesis of new" exact="viral" post="genome copies, which translates lesser formation of novel infectious"/>
  <result pre="new viral genome copies, which translates lesser formation of novel" exact="infectious" post="viral particles, does not affect latent virus within host"/>
  <result pre="viral genome copies, which translates lesser formation of novel infectious" exact="viral" post="particles, does not affect latent virus within host neurons"/>
  <result pre="latent virus within host neurons and hence, does not cure" exact="infection" post="(Poole and James, 2018). Other limitations related to the"/>
  <result pre="by acquiring point mutations in the gene encoding for the" exact="viral" post="thymidine kinase (TK), which decreases enzyme expression or modifies"/>
  <result pre="or by acquiring mutations in the gene encoding for the" exact="viral" post="DNA polymerase (UL30), which may enable HSV-1 and HSV-2"/>
  <result pre="(Spruance, 1993). Furthermore, within this scenario, the recovery time of" exact="cutaneous" post="lesions was found to be larger in the treated"/>
  <result pre="reduce healing time in approximately one or two days during" exact="herpes" post="labialis (Bean, 1992; Evans et al., 2000) and three"/>
  <result pre="(Bean, 1992; Evans et al., 2000) and three days in" exact="genital herpes" post="infections (Thin et al., 1983; Leflore et al., 2000)."/>
  <result pre="1992; Evans et al., 2000) and three days in genital" exact="herpes" post="infections (Thin et al., 1983; Leflore et al., 2000)."/>
  <result pre="Evans et al., 2000) and three days in genital herpes" exact="infections" post="(Thin et al., 1983; Leflore et al., 2000). Valacyclovir,"/>
  <result pre="there are other alternatives to treat skin lesions caused by" exact="herpes" post="simplex viruses, such as valacyclovir, penciclovir, and famciclovir, which"/>
  <result pre="mechanism of action that interferes with the function of the" exact="viral" post="DNA polymerase (De Clercq, 2013). These compounds differ from"/>
  <result pre="recommendation of their use to treat skin lesions caused by" exact="herpes" post="simplex virus infections (Chi et al., 2015; Chen et"/>
  <result pre="use to treat skin lesions caused by herpes simplex virus" exact="infections" post="(Chi et al., 2015; Chen et al., 2016). Valacyclovir"/>
  <result pre="also been approved for the treatment of HSV-1 and HSV-2" exact="infections" post="and clinical manifestations produced by HSV-1 and HSV-2, such"/>
  <result pre="produced by HSV-1 and HSV-2, such as cold sores and" exact="recurrent" post="genital herpes, as well as VZV and cytomegalovirus (Ormrod"/>
  <result pre="by HSV-1 and HSV-2, such as cold sores and recurrent" exact="genital herpes," post="as well as VZV and cytomegalovirus (Ormrod et al.,"/>
  <result pre="(Ormrod et al., 2000). Furthermore, famciclovir is approved for treating" exact="herpes" post="viruses, such as HSV-1 and HSV-2 (genital herpes and"/>
  <result pre="for treating herpes viruses, such as HSV-1 and HSV-2 (genital" exact="herpes" post="and orolabial herpes), as well as VZV (Simpson and"/>
  <result pre="orolabial herpes), as well as VZV (Simpson and Lyseng-Williamson, 2006)." exact="Resistance" post="to valacyclovir, penciclovir, and famciclovir can occur. Furthermore, there"/>
  <result pre="Ganciclovir is a nucleic acid analog that does not require" exact="viral" post="proteins for its activation in the cell (i.e., viral"/>
  <result pre="require viral proteins for its activation in the cell (i.e.," exact="viral" post="TK) (Markham and Faulds, 1994; Prichard et al., 2011;"/>
  <result pre="Ganciclovir is indicated for the treatment of CMV, particularly for" exact="systemic" post="and ocular infections in immunosuppressed patients (Buhles et al.,"/>
  <result pre="indicated for the treatment of CMV, particularly for systemic and" exact="ocular" post="infections in immunosuppressed patients (Buhles et al., 1988; Poole"/>
  <result pre="for the treatment of CMV, particularly for systemic and ocular" exact="infections" post="in immunosuppressed patients (Buhles et al., 1988; Poole and"/>
  <result pre="and HSV-2 and may be used for the treatment of" exact="herpetic keratitis" post="(Smee et al., 1983; Matthews and Boehme, 1988; Chou"/>
  <result pre="HSV-2 and may be used for the treatment of herpetic" exact="keratitis" post="(Smee et al., 1983; Matthews and Boehme, 1988; Chou"/>
  <result pre="together with femtosecond laser-assisted corneal debridement in the treatment of" exact="herpes" post="simplex virus epithelial keratitis (ClinicalTrials.gov NCT03217474). Of note, ganciclovir"/>
  <result pre="laser-assisted corneal debridement in the treatment of herpes simplex virus" exact="epithelial" post="keratitis (ClinicalTrials.gov NCT03217474). Of note, ganciclovir has been reported"/>
  <result pre="corneal debridement in the treatment of herpes simplex virus epithelial" exact="keratitis" post="(ClinicalTrials.gov NCT03217474). Of note, ganciclovir has been reported to"/>
  <result pre="altered mental status, anxiety, ataxia, tremors, convulsions, fever, abnormal levels" exact="of liver" post="enzymes in serum, diarrhea, and nausea, among others (Kimberlin"/>
  <result pre="each other, these two compounds affect different steps in the" exact="viral" post="replication cycle. Cidofovir acts as a nucleotide analog and"/>
  <result pre="analog and polymerase inhibitor with a high affinity for the" exact="viral" post="DNA polymerase, with cidofovir-diphosphate having 25–50 fold higher affinity"/>
  <result pre="polymerase, with cidofovir-diphosphate having 25–50 fold higher affinity for the" exact="viral" post="DNA polymerase than the host DNA polymerase, causing thus"/>
  <result pre="causing thus a more effective block in the replication of" exact="viral" post="DNA than acyclovir (Ho et al., 1991). Importantly, cidofovir"/>
  <result pre="this drug has not been approved for the treatment of" exact="herpes" post="simplex viruses in humans. Yet, a clinical study was"/>
  <result pre="(ClinicalTrials.gov Identifier: NCT00002116). On the other hand, foscarnet inhibits the" exact="viral" post="DNA polymerase of herpesviruses by binding near to the"/>
  <result pre="resistance to foscarnet only occurs because of mutations in the" exact="viral" post="DNA polymerase gene (Reusser, 1996). Regretfully, these two drugs"/>
  <result pre="adverse effects in patients, such as nephrotoxicity, azotemia, proteinuria, crystalluria," exact="interstitial nephritis," post="acute tubular necrosis, increases in the concentrations of creatinine"/>
  <result pre="in patients, such as nephrotoxicity, azotemia, proteinuria, crystalluria, interstitial nephritis," exact="acute" post="tubular necrosis, increases in the concentrations of creatinine up"/>
  <result pre="and electrolytes that may result in the alterations indicated above." exact="Resistance" post="to foscarnet has been observed in immuno- compromised individuals,"/>
  <result pre="the isolate showing mutations that truncated the C-terminal of the" exact="viral" post="DNA polymerase (Wyles et al., 2005). Notably, cidofovir resistance"/>
  <result pre="because ganciclovir produced adverse effects. Unfortunately, these children showed HSV-related" exact="stomatitis" post="during cidofovir treatment and the authors suggested that the"/>
  <result pre="to both, ACV and foscarnet in a girl with lymphatic" exact="leukemia" post="indicated that only cidofovir treatment was successful at helping"/>
  <result pre="indicated that only cidofovir treatment was successful at helping avoid" exact="recurrent" post="oral stomatitis (Bryant et al., 2001). Due to the"/>
  <result pre="only cidofovir treatment was successful at helping avoid recurrent oral" exact="stomatitis" post="(Bryant et al., 2001). Due to the somewhat reduced"/>
  <result pre="mentioned above in the treatment of skin lesions caused by" exact="herpes" post="simplex viruses, new therapeutic alternatives have emerged in the"/>
  <result pre="another drug marketed to treat skin lesions due to HSV-2" exact="infection" post="is Viroxyn® (Quadex Pharmaceuticals), which consists of benzalkonium chloride,"/>
  <result pre="preservative. This compound would act as a virucidal agent over" exact="herpes" post="simplex viruses (Bélec et al., 2000). Although Viroxyn has"/>
  <result pre="been sold for more than 16 years, there are only" exact="limited" post="studies that have evaluated its effectiveness, some proposing that"/>
  <result pre="of action Type of molecule Status References Acyclovir Inhibitor of" exact="viral" post="DNA replication Nucleoside analog Approved by FDA and EMA"/>
  <result pre="FDA and EMA Gnann et al., 1983 Valacyclovir Inhibitor of" exact="viral" post="DNA replication Nucleoside analog Approved by FDA and EMA"/>
  <result pre="FDA and EMA Schuster et al., 2016 Penciclovir Inhibitor of" exact="viral" post="DNA replication Nucleoside analog Approved by FDA and EMA"/>
  <result pre="FDA and EMA Meira et al., 2019 Famciclovir Inhibitor of" exact="viral" post="DNA replication Nucleoside analog Approved by FDA and EMA"/>
  <result pre="Approved by FDA and EMA Mondal, 2007 Ganciclovir Inhibitor of" exact="viral" post="DNA replication Nucleoside analog Approved by FDA and EMA"/>
  <result pre="FDA and EMA Al-Badr and Ajarim, 2018 Foscarnet Inhibitor of" exact="viral" post="DNA replication Pyrophosphate analog Approved by FDA and EMA"/>
  <result pre="Approved by FDA and EMA Crumpacker, 1992 Cidofovir Inhibitor of" exact="viral" post="DNA replication Nucleotide analog Approved by FDA and EMA"/>
  <result pre="Approved by FDA and EMA Lea and Bryson, 1996 Docosanol" exact="Viral" post="entry inhibitor Saturated alcohol Approved by FDA and EMA"/>
  <result pre="the United States Taylor-Robinson and Ballard, 2001 Idoxuridine Inhibitor of" exact="viral" post="DNA replication Deoxyuridine analog Approved by FDA and EMA"/>
  <result pre="and Li, 2016; Roozbahani and Hammersmith, 2018 Vidarabine Inhibitor of" exact="viral" post="DNA replication Nucleoside analog Approved by FDA and EMA"/>
  <result pre="FDA and EMA Chou and Hong, 2014 Trifluridine Inhibitor of" exact="viral" post="DNA replication Nucleoside analog Approved by FDA and EMA"/>
  <result pre="Approved by FDA and EMA Wilhelmus, 2015 Brivudine Inhibitor of" exact="viral" post="DNA replication Nucleoside analog Approved by EMA De Clercq,"/>
  <result pre="analog Approved by EMA De Clercq, 2019 Brincidofovir Inhibitor of" exact="viral" post="DNA replication Nucleotide analog Under FDA Review Lee et"/>
  <result pre="Under FDA Review Lee et al., 2018 Amenamevir Inhibitor of" exact="viral" post="DNA replication Helicase-Primase inhibitor Being assessed in clinical trials"/>
  <result pre="in clinical trials Kawashima et al., 2017 Pritelivir Inhibitor of" exact="viral" post="DNA replication Helicase-Primase inhibitor Being assessed in clinical trials"/>
  <result pre="al., 2014 Nelfinavir mesylate Inhibits the maturation and export of" exact="viral" post="particles HIV-1 protease inhibitor Being assessed in clinical trials"/>
  <result pre="is also a nucleoside analogs is mainly used to treat" exact="herpetic keratitis." post="Idoxuridine is a thymidine (pyrimidine) analog that was identified"/>
  <result pre="was identified as the first effective topical agent against HSV" exact="infection" post="(Chou and Hong, 2014; Wilhelmus, 2015), and was mainly"/>
  <result pre="and was mainly used topically as an ointment for treating" exact="epithelial" post="keratitis caused by HSV-1 infection of the corneal epithelium"/>
  <result pre="was mainly used topically as an ointment for treating epithelial" exact="keratitis" post="caused by HSV-1 infection of the corneal epithelium (Roozbahani"/>
  <result pre="as an ointment for treating epithelial keratitis caused by HSV-1" exact="infection" post="of the corneal epithelium (Roozbahani and Hammersmith, 2018). However,"/>
  <result pre="it is also poorly soluble and therefore its use is" exact="limited" post="to topical formulations, being less preferable than other current"/>
  <result pre="pyrimidine nucleoside that is frequently used for the treatment of" exact="herpetic keratitis" post="as a topical formulation. This drug was approved by"/>
  <result pre="nucleoside that is frequently used for the treatment of herpetic" exact="keratitis" post="as a topical formulation. This drug was approved by"/>
  <result pre="for its use as a 1% solution treatment for HSV-related" exact="keratitis" post="and is at present one of the most common"/>
  <result pre="a pyrimidine analog that acts as a prodrug, phosphorylated by" exact="viral" post="thymidine kinase only and thus targeting the viral DNA"/>
  <result pre="phosphorylated by viral thymidine kinase only and thus targeting the" exact="viral" post="DNA polymerase (Wilhelmus, 2015). This compound has been proven"/>
  <result pre="least as effective as acyclovir in the treatment of HSV-1" exact="infection" post="(Chou and Hong, 2014). Currently, is mainly used in"/>
  <result pre="is mainly used in different countries for treatment of VZV" exact="infections" post="(De Clercq, 2019). Compounds Against HSVs Currently Being Assessed"/>
  <result pre="compound is phosphorylated, acting as a substrate inhibitor for the" exact="viral" post="DNA polymerase. Noteworthy, brincidofovir accumulates within the cell significantly"/>
  <result pre="NCT01143181). On the other hand, amenamevir and pritelivir target the" exact="viral" post="DNA helicase/primase complex (H/P) (Kleymann et al., 2002; Poole"/>
  <result pre="phase for immunocompromised subjects with acyclovir-resistant mucocutaneous HSV-1 or HSV-2" exact="infection" post="(ClinicalTrials.gov Identifier: NCT03073967). Amenamevir is an oxadiazolephenyl derivate that"/>
  <result pre="other herpesviruses and to inhibit the maturation and export of" exact="viral" post="particles (Kalu et al., 2014). As a consequence, nelfinavir"/>
  <result pre="as dengue (Lee et al., 2006; Pujol et al., 2012)," exact="avian influenza" post="(Gerber et al., 1958), HIV (Lee et al., 1999;"/>
  <result pre="Also, numerous studies have reported algae with antiviral activity against" exact="herpes" post="simplex viruses (Faral-Tello et al., 2012; Ribeiro et al.,"/>
  <result pre="alga Stypopodium zonale (Ochrophyta) against HSV-1 was related to the" exact="secondary" post="metabolite atomaric acid (Figure 1) (Ribeiro et al., 2012)."/>
  <result pre="FIGURE 1 Structure of botanical molecules with antiviral activity against" exact="herpes" post="simplex viruses. Structure of molecules derived from (A) algae,"/>
  <result pre="both viruses. Molecular structures were drawn using ACD/ChemSketchTM, (version 2018.1.1," exact="Advanced" post="Chemistry Development, Inc., Toronto, ON, Canada, www.acdlabs.com, 2019). Griffithsin"/>
  <result pre="the other hand, Osmundaria obtusiloba, an algae obtained from the" exact="Brazilian" post="coast was reported to have antiviral activity against both,"/>
  <result pre="was suggested to be mediated by algae glycolipids interacting with" exact="viral" post="glycoproteins (Souza et al., 2012). Padina pavonia, another algae"/>
  <result pre="with anti HSV-1 activity (Figure 1). Notably, this study reported" exact="total" post="viral inhibition when the evaluated compound was added to"/>
  <result pre="anti HSV-1 activity (Figure 1). Notably, this study reported total" exact="viral" post="inhibition when the evaluated compound was added to human"/>
  <result pre="might be mediated by the inhibition of virus replication and/or" exact="viral" post="protein synthesis (Lopes et al., 2017). Another alga which"/>
  <result pre="antiviral activity against HSV was observed in early stages of" exact="infection" post="affecting the attachment of HSV. Additionally, it was shown"/>
  <result pre="the attachment of HSV. Additionally, it was shown experimentally that" exact="viral" post="protein synthesis was affected through the evaluation of the"/>
  <result pre="was affected through the evaluation of the expression of the" exact="viral" post="protein VP5, as well as the cellular localization of"/>
  <result pre="molecule References Algae Hypnea musciformis (Hooked Weed) Virucidal, inhibition of" exact="viral" post="binding, inhibition of viral entry HSV-1 ✓ Unknown or"/>
  <result pre="musciformis (Hooked Weed) Virucidal, inhibition of viral binding, inhibition of" exact="viral" post="entry HSV-1 ✓ Unknown or not reported Unknown or"/>
  <result pre="Atomaric acid Ribeiro et al., 2012 Scinaia hatei Inhibition of" exact="viral" post="entry HSV-1 and HSV-2 ✓ Unknown or not reported"/>
  <result pre="Xylan (1,4-β-D-xylopyranosyl) Damonte et al., 2009 Osmundaria obtusiloba Interaction with" exact="viral" post="glycoproteins HSV-1 and HSV-2 ✓ Unknown or not reported"/>
  <result pre="Souza et al., 2012 Padina pavonica (Peacock’s Tail) Inhibition of" exact="viral" post="binding HSV-1 ✓ ✓ Fucoidan Hayashi et al., 2008"/>
  <result pre="✓ Fucoidan Hayashi et al., 2008 Haematococcus pluvialis Inhibition of" exact="viral" post="binding, inhibition of viral entry HSV-1 ✓ Unknown or"/>
  <result pre="al., 2008 Haematococcus pluvialis Inhibition of viral binding, inhibition of" exact="viral" post="entry HSV-1 ✓ Unknown or not reported Unknown or"/>
  <result pre="not reported Santoyo et al., 2012 Cystoseira myrica (False Sargassum)" exact="Viral" post="inhibition before and after absorption HSV-1 ✓ Unknown or"/>
  <result pre="not reported Zandi et al., 2007 Enteromorpha compressa Inhibition of" exact="viral" post="replication, inhibition of viral protein synthesis HSV-1 ✓ Unknown"/>
  <result pre="al., 2007 Enteromorpha compressa Inhibition of viral replication, inhibition of" exact="viral" post="protein synthesis HSV-1 ✓ Unknown or not reported Sulfated"/>
  <result pre="Lopes et al., 2017 Eucheuma gelatinae (Guso) Virucidal, inhibition of" exact="viral" post="binding, inhibition of viral gene expression HSV-1 ✓ Unknown"/>
  <result pre="Eucheuma gelatinae (Guso) Virucidal, inhibition of viral binding, inhibition of" exact="viral" post="gene expression HSV-1 ✓ Unknown or not reported Sulfated"/>
  <result pre="et al., 2015 Griffithsia sp. (Griffiths’s Coral Weed) Inhibition of" exact="viral" post="binding, inhibition of viral entry HSV-2 ✓ ✓ Griffithsin"/>
  <result pre="sp. (Griffiths’s Coral Weed) Inhibition of viral binding, inhibition of" exact="viral" post="entry HSV-2 ✓ ✓ Griffithsin Nixon et al., 2013;"/>
  <result pre="ether Park et al., 2014 Undaria pinnatifida (Wakame) Inhibition of" exact="viral" post="binding HSV-1 and HSV-2 ✓ ✓ Fucoidan Hayashi et"/>
  <result pre="✓ Fucoidan Hayashi et al., 2008; Lee et al., 2004" exact="Fungi" post="Aspergillus ruber Inhibition of viral binding, inhibition of entry"/>
  <result pre="2008; Lee et al., 2004 Fungi Aspergillus ruber Inhibition of" exact="viral" post="binding, inhibition of entry HSV-1 ✓ Unknown or not"/>
  <result pre="– E Rowley et al., 2003 Inonotus obliquus Inhibition of" exact="viral" post="binding, inhibition of viral entry HSV-1 ✓ Unknown or"/>
  <result pre="al., 2003 Inonotus obliquus Inhibition of viral binding, inhibition of" exact="viral" post="entry HSV-1 ✓ Unknown or not reported aqueous extract"/>
  <result pre="Pradeep et al., 2019 Ganoderma lucidum (Lingzhi Mushroom) Inhibition of" exact="viral" post="binding, inhibition of viral entry HSV-1 and HSV-2 ✓"/>
  <result pre="Ganoderma lucidum (Lingzhi Mushroom) Inhibition of viral binding, inhibition of" exact="viral" post="entry HSV-1 and HSV-2 ✓ Unknown or not reported"/>
  <result pre="Eo et al., 2000 Agaricus brasiliensis (Almond Mushroom) Inhibition of" exact="viral" post="binding, inhibition of viral entry HSV-1 and HSV-2 Unknown"/>
  <result pre="Agaricus brasiliensis (Almond Mushroom) Inhibition of viral binding, inhibition of" exact="viral" post="entry HSV-1 and HSV-2 Unknown or not reported ✓"/>
  <result pre="et al., 2013 Grifola frondosa (Maltake) Virucidal HSV-1 ✓ ✓" exact="Protein" post="Gu et al., 2007 Rozites caperata Unknown or not"/>
  <result pre="et al., 2019 Plants Peganum harmala (Wild Rue) Inhibition of" exact="viral" post="entry HSV-2 ✓ Unknown or not reported Harmine Benzekri"/>
  <result pre="Coto, 2009; Barquero et al., 1997 Labiatae Virucidal, inhibition of" exact="viral" post="binding, inhibition of viral entry HSV-1 and HSV-2 ✓"/>
  <result pre="al., 1997 Labiatae Virucidal, inhibition of viral binding, inhibition of" exact="viral" post="entry HSV-1 and HSV-2 ✓ Unknown or not reported"/>
  <result pre="not reported Brand et al., 2016 Verbenaceae Virucidal, inhibition of" exact="viral" post="binding, inhibition of viral entry HSV-1 and HSV-2 ✓"/>
  <result pre="al., 2016 Verbenaceae Virucidal, inhibition of viral binding, inhibition of" exact="viral" post="entry HSV-1 and HSV-2 ✓ Unknown or not reported"/>
  <result pre="not reported Brand et al., 2016 Glechon spathulata Inhibition after" exact="viral" post="attachment HSV-1 ✓ Unknown or not reported Bicyclogermacrene Venturi"/>
  <result pre="reported Bicyclogermacrene Venturi et al., 2015 Glechon marifolia Inhibition after" exact="viral" post="attachment HSV-1 ✓ Unknown or not reported Bicyclogermacrene Venturi"/>
  <result pre="et al., 2015 Aglaia odorata (Chinese Perfume Plant) Inhibition after" exact="viral" post="attachment HSV-1 Unknown or not reported ✓ Unknown or"/>
  <result pre="reported Lipipun et al., 2003 Moringa oleifera (Moringa) Inhibition after" exact="viral" post="attachment HSV-1 Unknown or not reported ✓ Unknown or"/>
  <result pre="not reported Lipipun et al., 2003 Ventilago denticulata Inhibition after" exact="viral" post="attachment HSV-1 Unknown or not reported ✓ Unknown or"/>
  <result pre="2003 Morus alba (White Mulberry) Inhibition of early stages of" exact="viral infection" post="HSV-1 and HSV-2 ✓ Unknown or not reported Kuwanon"/>
  <result pre="Morus alba (White Mulberry) Inhibition of early stages of viral" exact="infection" post="HSV-1 and HSV-2 ✓ Unknown or not reported Kuwanon"/>
  <result pre="Houttuynia cordata (Fish Mint) Inhibition of NF-κB activation, inhibition of" exact="viral" post="binding, inhibition of viral entry HSV-1 and HSV-2 ✓"/>
  <result pre="Inhibition of NF-κB activation, inhibition of viral binding, inhibition of" exact="viral" post="entry HSV-1 and HSV-2 ✓ Unknown or not reported"/>
  <result pre="2011 and Hung et al., 2015 Veratum grandiflorum Inhibition of" exact="viral" post="replication HSV-1 and HSV-2 ✓ Unknown or not reported"/>
  <result pre="not reported Mahmoud, 2017 Eucalyptus sideroxylon (Mugga) Virucidal, inhibition of" exact="viral" post="entry, post-infection antiviral effects HSV-1 and HSV-2 ✓ Unknown"/>
  <result pre="which has been shown to be capable of inhibiting HSV" exact="infection" post="in a murine model of HSV-2 infection (Figure 1)"/>
  <result pre="of inhibiting HSV infection in a murine model of HSV-2" exact="infection" post="(Figure 1) (Nixon et al., 2013). The mechanism of"/>
  <result pre="consists on its binding to mannose N-glycosylations that blocks the" exact="infection" post="process of HSV-2 and inhibits cell-to-cell spread of the"/>
  <result pre="of infection. The study showed a strong reduction in HSV-2" exact="infection" post="when applied together as a prophylactic, namely between 10"/>
  <result pre="prophylactic, namely between 10 min and 1 h prior to" exact="infection" post="(Levendosky et al., 2015). A more recent article reported"/>
  <result pre="the efficacy of Griffithsin in combination with carrageenan against HSV-2" exact="infections" post="together with HPV and HIV-1, which was evaluated in"/>
  <result pre="these compounds has also been evaluated in a murine model" exact="skin infection," post="which showed decreased skin lesions compared to controls when"/>
  <result pre="skin lesions compared to controls when administrated 4 h before" exact="infection" post="and then three times per day for 6–10 days."/>
  <result pre="effect of fucoidan was tested in another study against corneal" exact="infection" post="with HSV-1, a reduction in herpetic lesions was found"/>
  <result pre="HSV-2 to Vero cells, inhibiting the early phase of HSV-2" exact="infection" post="(Alboofetileh et al., 2019). Table 2 summarizes the antiviral"/>
  <result pre="polysaccharides named SHAP-1 and SHAP-2, which were later evaluated in" exact="viral" post="plaque formation assay for both HSV-1 and HSV-2 virus."/>
  <result pre="penetration assays suggest an antiviral effect at early stages of" exact="infection" post="(Sun et al., 2019). Fungus-Derived Compounds With Antiviral Activity"/>
  <result pre="HSV-2. The fungus Aspergillus versicolor has been shown to produce" exact="secondary" post="metabolites, such as anthraquinones with anti-herpetic activity (Figure 1)."/>
  <result pre="the Aspergillus genus showed antiviral activity against HSV-1, with two" exact="secondary" post="metabolites flavoglaucin and isodihydroauroglaucin derived from A. ruber being"/>
  <result pre="extract from Inonotus obliquus (AEIO) was shown to inhibit HSV-1" exact="infection" post="in Vero cells (Pradeep et al., 2019). the antiviral"/>
  <result pre="2019). the antiviral activity was detected at early times during" exact="viral infection," post="suggesting AEIO blocks viral entry, particularly membrane fusion (Pradeep"/>
  <result pre="detected at early times during viral infection, suggesting AEIO blocks" exact="viral" post="entry, particularly membrane fusion (Pradeep et al., 2019). Interestingly,"/>
  <result pre="(Pradeep et al., 2019). Interestingly, fungus proteins that inhibit HSV" exact="infection" post="have also been identified. Two proteins that bind polysaccharides"/>
  <result pre="and HSV-2 (De Sousa Cardozo et al., 2014). MI-S inhibited" exact="viral" post="adsorption and penetration into Vero cells and had a"/>
  <result pre="compound was also shown to reduce the severity of HSV-2" exact="disease" post="in a murine genital infection model with one single"/>
  <result pre="reduce the severity of HSV-2 disease in a murine genital" exact="infection" post="model with one single application (Cardozo et al., 2013)."/>
  <result pre="shown to have virucidal effects in cell cultures and suppressed" exact="viral" post="entry into Vero cells (Gu et al., 2007). Furthermore,"/>
  <result pre="in blepharitis, vascularization and stromal disease, as well as reduced" exact="viral" post="replication in the cornea (Gu et al., 2007). Notably,"/>
  <result pre="and observed that this peptide decreased the severity of stromal" exact="keratitis" post="(Pradeep et al., 2019). Table 2 summarizes the antiviral"/>
  <result pre="and to interfere with virus entry (Benzekri et al., 2018)." exact="Essential" post="oils extracted from plants belonging to the Labiatae and"/>
  <result pre="essential oils for 48–72 h significantly reduced HSV-1 and HSV-2" exact="viral" post="titers. Interestingly, their mechanisms of action were found to"/>
  <result pre="identified antiviral activity against HSV-1, which was effective after the" exact="infection" post="of Vero cells (Figure 1) (Venturi et al., 2015)."/>
  <result pre="of E. camaldulensis were shown to inhibit HSV-1 and HSV-2" exact="infection" post="when the extracts were added to Vero cells during-"/>
  <result pre="the antiviral activities detected, there were compounds that also inhibited" exact="hepatitis" post="A, coxsackie and adenoviruses, besides HSV-1 and HSV-2. Interestingly,"/>
  <result pre="effect acting pre-treatment (virucidal), thus inhibiting virus entry and subsequent" exact="infection" post="processes, while the antiviral effect against HSV-1 was only"/>
  <result pre="extract was incubated with the virus previous to the cell" exact="infection" post="(Okba et al., 2017). In addition, twelve compounds isolated"/>
  <result pre="has antiviral activity over HSV at multiple steps of the" exact="infection" post="process, inhibiting cellular adsorption and penetration, as well as"/>
  <result pre="extracts from Houttuynia cordata, a Chinese herbal medicine, blocks HSV-2" exact="infection" post="by inhibiting NF-κB activation, a host transcription factor that"/>
  <result pre="that has been reported to be required for effective HSV" exact="infection" post="(Amici et al., 2006). In order to identify the"/>
  <result pre="studies have assessed the antiviral effects of plant-derived compounds against" exact="herpes" post="simplex virus in animal models either, alone or combined"/>
  <result pre="denticulate were shown to have antiviral effects against HSV-1 upon" exact="cutaneous" post="infections in BALB/c mice. Here, the plant extracts combined"/>
  <result pre="were shown to have antiviral effects against HSV-1 upon cutaneous" exact="infections" post="in BALB/c mice. Here, the plant extracts combined with"/>
  <result pre="compound is added to the inoculum for 1 h before" exact="viral infection" post="or immediately after viral infection (Rattanathongkom et al., 2009)."/>
  <result pre="is added to the inoculum for 1 h before viral" exact="infection" post="or immediately after viral infection (Rattanathongkom et al., 2009)."/>
  <result pre="inoculum for 1 h before viral infection or immediately after" exact="viral infection" post="(Rattanathongkom et al., 2009). The authors suggested that the"/>
  <result pre="for 1 h before viral infection or immediately after viral" exact="infection" post="(Rattanathongkom et al., 2009). The authors suggested that the"/>
  <result pre="2009). Moreover, Chikusetsusaponin IV showed antiviral activity against HSV-2 genital" exact="infection" post="in mice when administrated three times per day three"/>
  <result pre="mice when administrated three times per day three days before" exact="infection" post="and up to 7 days after infection (Rattanathongkom et"/>
  <result pre="three days before infection and up to 7 days after" exact="infection" post="(Rattanathongkom et al., 2009). Finally, Meliacine (MA) a glycopeptide"/>
  <result pre="showed favorable results against HSV-2 in a mouse model of" exact="infection" post="when applied topically immediately after infection with HSV-2 (Petrera"/>
  <result pre="a mouse model of infection when applied topically immediately after" exact="infection" post="with HSV-2 (Petrera and Coto, 2009). Table 2 summarizes"/>
  <result pre="way to validate potential new drugs for the treatment of" exact="herpes" post="simplex virus manifestations. Regarding herpes labialis, a Neem tree-based"/>
  <result pre="drugs for the treatment of herpes simplex virus manifestations. Regarding" exact="herpes" post="labialis, a Neem tree-based cream (Azadirachta indica) called TheraNeem"/>
  <result pre="best of our knowledge. Another study involving the treatment of" exact="herpes" post="labialis lesions was performed with Huanglian-Jiedu Decoction, a Chinese"/>
  <result pre="to date. Additionally, a randomized controlled open-label superiority trial for" exact="herpes" post="simplex virus labial episodes was recently performed with medical-grade"/>
  <result pre="both, in cell culture assays and in animal studies against" exact="herpes" post="simplex viruses (HSV-1 and HSV-2). Interestingly, several mechanisms of"/>
  <result pre="are inhibition of virus-entry into the target cells, inhibition of" exact="viral" post="protein expression and interference with viral DNA replication, which"/>
  <result pre="target cells, inhibition of viral protein expression and interference with" exact="viral" post="DNA replication, which are all essential processes for generating"/>
  <result pre="DNA replication, which are all essential processes for generating novel" exact="infectious" post="viral particles (Ibáñez et al., 2017). For botanical extracts"/>
  <result pre="replication, which are all essential processes for generating novel infectious" exact="viral" post="particles (Ibáñez et al., 2017). For botanical extracts in"/>
  <result pre="clinical application seems most likely oriented toward topical treatments for" exact="cutaneous" post="or mucosal manifestations elicited by these viruses, although some"/>
  <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
  <result pre="(2017). Antiviral activity of Eucalyptus camaldulensis leaves ethanolic extract on" exact="herpes" post="viruses infection.Int. J. Clin. Virol.1001–9. AkramM.TahirI. M.ShahS. M. A.MahmoodZ.AltafA.AhmadK.et"/>
  <result pre="recruitment on the IκBα promoter and directing the factor on" exact="viral" post="genes.J. Biol. Chem.2817110–7117. 10.1074/jbc.m51236620016407234 ArduinoP. G.PorterS. R. (2007). Herpes"/>
  <result pre="Biol. Chem.2817110–7117. 10.1074/jbc.m51236620016407234 ArduinoP. G.PorterS. R. (2007). Herpes simplex virus" exact="type 1" post="infection: overview on relevant clinico-pathological features.J. Oral. Pathol. Med.37107–121."/>
  <result pre="Clin Microbiol.26662–667. 10.1128/jcm.26.4.662-667.19882835389 BaconT. H.BoonR. J.SchultzM.Hodges-SavolaC. (2002). Surveillance for antiviral-agent-resistant" exact="herpes" post="simplex virus in the general population with recurrent herpes"/>
  <result pre="for antiviral-agent-resistant herpes simplex virus in the general population with" exact="recurrent" post="herpes labialis.Antimicrob. Agents Chemother.463042–3044. 10.1128/aac.46.9.3042-3044.200212183267 BaconT. H.LevinM. J.LearyJ. J.SariskyR."/>
  <result pre="antiviral-agent-resistant herpes simplex virus in the general population with recurrent" exact="herpes" post="labialis.Antimicrob. Agents Chemother.463042–3044. 10.1128/aac.46.9.3042-3044.200212183267 BaconT. H.LevinM. J.LearyJ. J.SariskyR. T.SuttonD."/>
  <result pre="replication of a thymidine kinase-deficient mutant of Herpes simplex virus" exact="type 1" post="alone and in combination with acyclovir.Int. J. Antimicrob. Agents949–55."/>
  <result pre="T.et al. (2012). Efficacy results of a trial of a" exact="herpes" post="simplex vaccine.N. Engl. J. Med.36634–43. 10.1056/NEJMoa110315122216840 BenedettiJ.CoreyL.AshleyR. (1994). Recurrence"/>
  <result pre="vaccine.N. Engl. J. Med.36634–43. 10.1056/NEJMoa110315122216840 BenedettiJ.CoreyL.AshleyR. (1994). Recurrence rates in" exact="genital herpes" post="after symptomatic first-episode infection.Ann. Intern. Med.121847–854. 7978697 BenzekriR.BouslamaL.PapettiA.HammamiM.SmaouiA.LimamF. (2018)."/>
  <result pre="Engl. J. Med.36634–43. 10.1056/NEJMoa110315122216840 BenedettiJ.CoreyL.AshleyR. (1994). Recurrence rates in genital" exact="herpes" post="after symptomatic first-episode infection.Ann. Intern. Med.121847–854. 7978697 BenzekriR.BouslamaL.PapettiA.HammamiM.SmaouiA.LimamF. (2018)."/>
  <result pre="Med.36634–43. 10.1056/NEJMoa110315122216840 BenedettiJ.CoreyL.AshleyR. (1994). Recurrence rates in genital herpes after" exact="symptomatic" post="first-episode infection.Ann. Intern. Med.121847–854. 7978697 BenzekriR.BouslamaL.PapettiA.HammamiM.SmaouiA.LimamF. (2018). Anti HSV-2"/>
  <result pre="10.1016/j.micpath.2017.12.01729223449 BlotN.SchneiderP.YoungP.JanvresseC.DehesdinD.TronP.et al. (2000). Treatment of an acyclovir and foscarnet-resistant" exact="herpes" post="simplex virus infection with cidofovir in a child after"/>
  <result pre="al. (2000). Treatment of an acyclovir and foscarnet-resistant herpes simplex" exact="virus infection" post="with cidofovir in a child after an unrelated bone"/>
  <result pre="(2000). Treatment of an acyclovir and foscarnet-resistant herpes simplex virus" exact="infection" post="with cidofovir in a child after an unrelated bone"/>
  <result pre="Oil Res.28130–137. 10.1080/10412905.2015.1093556 BrezániV.LelákováV.HassanS. T. S.Berchová-BímováK.NovýP.KloučekP.et al. (2018). Anti-infectivity against" exact="herpes" post="simplex virus and selected microbes and anti-inflammatory activities of"/>
  <result pre="Eucalyptus globulus labill.Viruses10:360. 10.3390/v1007036029986399 BryantP.SasadeuszJ.CarapetisJ.WatersK.CurtisN. (2001). Successful treatment of foscarnet-resistant" exact="herpes" post="simplex stomatitis with intravenous cidofovir in a child.Pediatr. Infect."/>
  <result pre="labill.Viruses10:360. 10.3390/v1007036029986399 BryantP.SasadeuszJ.CarapetisJ.WatersK.CurtisN. (2001). Successful treatment of foscarnet-resistant herpes simplex" exact="stomatitis" post="with intravenous cidofovir in a child.Pediatr. Infect. Dis. J.201083–1086."/>
  <result pre="Agaricus brasiliensis mycelial polysaccharide.Antimicrob. Agents Chemother.572541–2549. 10.1128/AAC.02250-1223507287 ChauT. (2018). Acyclovir" exact="neurotoxicity" post="in a peritoneal dialysis patient: report of a case"/>
  <result pre="Efficacy and safety of nucleoside antiviral drugs for treatment of" exact="recurrent" post="herpes labialis: a systematic review and meta-analysis.J. Oral. Pathol."/>
  <result pre="and safety of nucleoside antiviral drugs for treatment of recurrent" exact="herpes" post="labialis: a systematic review and meta-analysis.J. Oral. Pathol. Med.46561–568."/>
  <result pre="meta-analysis.J. Oral. Pathol. Med.46561–568. 10.1111/jop.1253427935123 ChenX.QiaoH.LiuT.YangZ.XuL.XuY.et al. (2012). Inhibition of" exact="herpes" post="simplex virus infection by oligomeric stilbenoids through ROS generation.Antiviral."/>
  <result pre="Pathol. Med.46561–568. 10.1111/jop.1253427935123 ChenX.QiaoH.LiuT.YangZ.XuL.XuY.et al. (2012). Inhibition of herpes simplex" exact="virus infection" post="by oligomeric stilbenoids through ROS generation.Antiviral. Res.9530–36. 10.1016/j.antiviral.2012.05.00122584350 ChenX.WangZ.YangZ.WangJ.XuY.TanR.et"/>
  <result pre="Med.46561–568. 10.1111/jop.1253427935123 ChenX.QiaoH.LiuT.YangZ.XuL.XuY.et al. (2012). Inhibition of herpes simplex virus" exact="infection" post="by oligomeric stilbenoids through ROS generation.Antiviral. Res.9530–36. 10.1016/j.antiviral.2012.05.00122584350 ChenX.WangZ.YangZ.WangJ.XuY.TanR.et"/>
  <result pre="generation.Antiviral. Res.9530–36. 10.1016/j.antiviral.2012.05.00122584350 ChenX.WangZ.YangZ.WangJ.XuY.TanR.et al. (2011). Houttuynia cordata blocks HSV" exact="infection" post="through inhibition of NF-κB activation.Antiviral. Res.92341–345. 10.1016/j.antiviral.2011.09.00521951655 ChenY. C.ShengJ.TrangP.LiuF."/>
  <result pre="C.WangS. H.DelamereF. M.WojnarowskaF.PetersM. C.KanjirathP. P. (2015). Interventions for prevention of" exact="herpes" post="simplex labialis (cold sores on the lips).Cochrane Database Syst."/>
  <result pre="lips).Cochrane Database Syst. Rev.8:CD010095. 10.1002/14651858.CD010095.pub226252373 ChilukuriS.RosenT. (2003). Management of acyclovir-resistant" exact="herpes" post="simplex virus.Dermatol Clin.21311–320. 10.1016/s0733-8635(02)00093-112757254 ChonoK.KatsumataK.KontaniT.KobayashiM.SudoK.YokotaT.et al. (2010). ASP2151, a"/>
  <result pre="novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and" exact="herpes" post="simplex virus types 1 and 2.J. Antimicrob. Chemother.651733–1741. 10.1093/jac/dkq19820534624"/>
  <result pre="Y. (2014). Ganciclovir ophthalmic gel 0.15% for the treatment of" exact="acute" post="herpetic keratitis: background, effectiveness, tolerability, safety, and future applications.Ther."/>
  <result pre="go-ahead signals.Integr. Med. Res.7109–125. 10.1016/j.imr.2018.03.00529989061 CoreyL.AdamsH. G.BrownZ. A.HolmesK. K. (1983)." exact="Genital herpes simplex" post="virus infections: clinical manifestations, course, and complications.Ann. Intern. Med.98958–972.6344712"/>
  <result pre="signals.Integr. Med. Res.7109–125. 10.1016/j.imr.2018.03.00529989061 CoreyL.AdamsH. G.BrownZ. A.HolmesK. K. (1983). Genital" exact="herpes" post="simplex virus infections: clinical manifestations, course, and complications.Ann. Intern."/>
  <result pre="manifestations, course, and complications.Ann. Intern. Med.98958–972.6344712 CowanF. M.JohnsonA. M.AshleyR.CoreyL.MindelA. (1994)." exact="Antibody" post="to herpes simplex virus type 2 as serological marker"/>
  <result pre="and complications.Ann. Intern. Med.98958–972.6344712 CowanF. M.JohnsonA. M.AshleyR.CoreyL.MindelA. (1994). Antibody to" exact="herpes" post="simplex virus type 2 as serological marker of sexual"/>
  <result pre="Med.98958–972.6344712 CowanF. M.JohnsonA. M.AshleyR.CoreyL.MindelA. (1994). Antibody to herpes simplex virus" exact="type 2" post="as serological marker of sexual lifestyle in populations.BMJ3091325–1329. 10.1136/bmj.309.6965.13257866079"/>
  <result pre="10.1136/bmj.309.6965.13257866079 CrumpackerC. S. (1992). Mechanism of action of foscarnet against" exact="viral" post="polymerases.Am. J. Med.92(2 Suppl. 1), 3s–7s. 1371038 DamonteE. B.PujolC."/>
  <result pre="and anti-HSV activity.Int. J. Biol. Macromol.46173–178. 10.1016/j.ijbiomac.2009.12.00320026104 De ClercqE. (2013)." exact="Selective" post="anti-herpesvirus agents.Antivir. Chem. Chemother.2393–101. 10.3851/IMP253323343513 De ClercqE. (2019). Fifty"/>
  <result pre="Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV" exact="infections" post="in vivo.Nat. Commun.9:1234567890. 10.1038/s41467-018-06349-030250170 DinhT. H.DunneE. F.MarkowitzL. E.WeinstockH.BermanS. (2008)."/>
  <result pre="in vivo.Nat. Commun.9:1234567890. 10.1038/s41467-018-06349-030250170 DinhT. H.DunneE. F.MarkowitzL. E.WeinstockH.BermanS. (2008). Assessing" exact="neonatal" post="herpes reporting in the United States, 2000-2005.Sex Transm. Dis.3519–21."/>
  <result pre="vivo.Nat. Commun.9:1234567890. 10.1038/s41467-018-06349-030250170 DinhT. H.DunneE. F.MarkowitzL. E.WeinstockH.BermanS. (2008). Assessing neonatal" exact="herpes" post="reporting in the United States, 2000-2005.Sex Transm. Dis.3519–21. 10.1097/olq.0b013e318162c4c618157062"/>
  <result pre="States, 2000-2005.Sex Transm. Dis.3519–21. 10.1097/olq.0b013e318162c4c618157062 DoiY.NinomiyaT.HataJ.YonemotoK.TanizakiY.ArimaH.et al. (2009). Seroprevalence of" exact="herpes" post="simplex virus 1 and 2 in a population-based cohort"/>
  <result pre="Japan.J. Epidemiol.1956–62. 10.2188/jea.je2008006119265271 DrenoB.MalkinJ. E.SaiagP.Batuji-GarinS. (2012). Patients’ profile, burden of" exact="disease" post="and quality of life in recurrent herpes labialis: a"/>
  <result pre="Patients’ profile, burden of disease and quality of life in" exact="recurrent" post="herpes labialis: a survey conducted in USA and France.J."/>
  <result pre="profile, burden of disease and quality of life in recurrent" exact="herpes" post="labialis: a survey conducted in USA and France.J. Eur."/>
  <result pre="Dermatol. Venereol.261458–1460. 10.1111/j.1468-3083.2011.04348.x22098071 DvorakC. C.CowanM. J.HornB.WeintrubP. S. (2009). Development of" exact="herpes" post="simplex virus stomatitis during receipt of cidofovir therapy.Clin. Infect."/>
  <result pre="DvorakC. C.CowanM. J.HornB.WeintrubP. S. (2009). Development of herpes simplex virus" exact="stomatitis" post="during receipt of cidofovir therapy.Clin. Infect. Dis.49e92–e95. 10.1086/60567819761410 EkorM."/>
  <result pre="monitoring safety.Front. Neurol.4:177. 10.3389/fphar.2013.0017724454289 EmmertD. H. (2000). Treatment of common" exact="cutaneous" post="herpes simplex virus infections.Am. Fam. Phys.611697–1706. 10750877 EoS. K.KimY."/>
  <result pre="safety.Front. Neurol.4:177. 10.3389/fphar.2013.0017724454289 EmmertD. H. (2000). Treatment of common cutaneous" exact="herpes" post="simplex virus infections.Am. Fam. Phys.611697–1706. 10750877 EoS. K.KimY. S.LeeC."/>
  <result pre="of acidic protein bound polysaccharide isolated from Ganoderma lucidum on" exact="herpes" post="simplex viruses.J. Ethnopharmacol.72475–481. 10.1016/s0378-8741(00)00266-x10996289 EvansT. G.BernsteinD. I.RabornG. W.HarmenbergJ.KowalskiJ.SpruanceS. L."/>
  <result pre="5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced" exact="herpes" post="labialis.Antimicrob. Agents Chemother.461870–1874. 10.1128/aac.46.6.1870-1874.200212019102 FaithS. A.SweetT. J.BaileyE.BoothT.DochertyJ. J. (2006)."/>
  <result pre="FaithS. A.SweetT. J.BaileyE.BoothT.DochertyJ. J. (2006). Resveratrol suppresses nuclear factor-κB in" exact="herpes" post="simplex virus infected cells.Antiviral. Res.72242–251. 10.1016/j.antiviral.2006.06.01116876885 Faral-TelloP.MirazoS.DutraC.PerezA.Geis-AsteggianteL.FrabasileS.et al. (2012)."/>
  <result pre="Faral-TelloP.MirazoS.DutraC.PerezA.Geis-AsteggianteL.FrabasileS.et al. (2012). Cytotoxic, virucidal, and antiviral activity of South" exact="American" post="plant and algae extracts.ScientificWorldJournal2012:174837. 10.1100/2012/17483722619617 FarooqA. V.ShuklaD. (2012). Herpes"/>
  <result pre="plant and algae extracts.ScientificWorldJournal2012:174837. 10.1100/2012/17483722619617 FarooqA. V.ShuklaD. (2012). Herpes simplex" exact="epithelial" post="and stromal keratitis: an epidemiologic update.Surv. Ophthalmol.57448–462. 10.1016/j.survophthal.2012.01.00522542912 FatahzadehM.SchwartzR."/>
  <result pre="keratitis: an epidemiologic update.Surv. Ophthalmol.57448–462. 10.1016/j.survophthal.2012.01.00522542912 FatahzadehM.SchwartzR. A. (2007). Human" exact="herpes" post="simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management.J."/>
  <result pre="M.JohnsonR. E.NahmiasA. J.AralS. O.LeeF. K.et al. (1997). Herpes simplex virus" exact="type 2" post="in the United States, 1976 to 1994.N. Engl. J."/>
  <result pre="(2015). Herbal plants and plant preparations as remedial approach for" exact="viral" post="diseases.VirusDisease26225–236. 10.1007/s13337-015-0276-626645032 GarozzoA.TimpanaroR.BisignanoB.FurneriP. M.BisignanoG.CastroA. (2009). In vitro antiviral activity"/>
  <result pre="seaweed extracts for chicken embryos infected with influenza B or" exact="mumps" post="virus.Proc. Soc. Exp. Biol. Med.99590–593. 10.3181/00379727-99-2442913614432 GnannJ. W.BartonN. H.WhitleyR."/>
  <result pre="(2001). A randomized clinical trial on the treatment of oral" exact="herpes" post="with topical zinc oxide/glycine.Altern. Ther. Heal. Med.749–56. 11347285 GuC."/>
  <result pre="of topical acyclovir, penciclovir, and docosanol for the treatment of" exact="herpes" post="simplex labialis.EMJ Dermatol.6118–123. HandelS.KlinglerE. J.WashburnK.BlankS.SchillingerJ. A. (2011). Population-based surveillance"/>
  <result pre="simplex labialis.EMJ Dermatol.6118–123. HandelS.KlinglerE. J.WashburnK.BlankS.SchillingerJ. A. (2011). Population-based surveillance for" exact="neonatal" post="herpes in New York City. April 2006-September 2010.Sex. Transm."/>
  <result pre="labialis.EMJ Dermatol.6118–123. HandelS.KlinglerE. J.WashburnK.BlankS.SchillingerJ. A. (2011). Population-based surveillance for neonatal" exact="herpes" post="in New York City. April 2006-September 2010.Sex. Transm. Dis.38705–711.21844721"/>
  <result pre="effects of a fucoidan from brown alga Undaria pinnatifida against" exact="herpes" post="simplex virus infection.Int. Immunopharmacol.8109–116. 10.1016/j.intimp.2007.10.01718068106 HoH.-T.WoodsK. L.De BoeckH.BronsonJ. J.MartinJ."/>
  <result pre="M. (1989). Mode of action of 9-(4-hydroxy-3-hydroxyemthylbut-1-yl)guanine (BRL 39123) against" exact="herpes" post="simplex virus in MRC-5 cells.Antimicrob. Agents Chemother.33223–229. 10.1128/aac.33.2.2232541655 HodgeR."/>
  <result pre="S.et al. (2015). Houttuynia cordata targets the beginning stage of" exact="herpes" post="simplex virus infection.PLoS One10:e0115475. 10.1371/journal.pone.011547525643242 IbáñezF. J.FaríasM. A.Gonzalez-TroncosoM. P.CorralesN.DuarteL."/>
  <result pre="al. (2018). Experimental dissection of the lytic replication cycles of" exact="herpes" post="simplex viruses in vitro.Front. Microbiol.9:2406. 10.3389/fmicb.2018.0240630386309 IbáñezF. J.FaríasM. A.Retamal-díazA.EspinozaJ."/>
  <result pre="(2017). Pharmacological induction of heme oxygenase-1 impairs nuclear accumulation of" exact="herpes" post="simplex virus capsids upon infection.Front. Microbiol.8:2108. 10.3389/fmicb.2017.0210829163402 JadhavP.KapoorN.ThomasB.LalH.KshirsagarN. (2012)."/>
  <result pre="(2012). Antiviral potential of selected indian medicinal (Ayurvedic) plants against" exact="herpes" post="simplex virus 1 and 2.N. Am. J. Med. Sci.4641–647.23272307"/>
  <result pre="Sci.4641–647.23272307 JamesS. H.PrichardM. N. (2014). Current and future therapies for" exact="herpes" post="simplex virus infections: mechanism of action and drug resistance.Curr."/>
  <result pre="resistance.Curr. Opin. Virol.854–61. 10.1016/j.coviro.2014.06.00325036916 JavalyK.WohlfeilerM.KalayjianR.KleinT.BrysonY.GraffordK.et al. (1999). Treatment of mucocutaneous" exact="herpes" post="simplex virus infections unresponsive to acyclovir with topical foscarnet"/>
  <result pre="10.1016/j.coviro.2014.06.00325036916 JavalyK.WohlfeilerM.KalayjianR.KleinT.BrysonY.GraffordK.et al. (1999). Treatment of mucocutaneous herpes simplex virus" exact="infections" post="unresponsive to acyclovir with topical foscarnet cream in AIDS"/>
  <result pre="C.FengH.LinY. C.GuoX. R. (2016). New strategies against drug resistance to" exact="herpes" post="simplex virus.Int. J. Oral. Sci.81–6. 10.1038/ijos.2016.327025259 JinF.ZhuoC.HeZ.WangH.LiuW.ZhangR.et al. (2015)."/>
  <result pre="gelatinae.World J. Microbiol. Biotechnol.31453–460. 10.1007/s11274-015-1798-125604263 JohnstonC.CoreyL. (2015). Current concepts for" exact="genital herpes" post="simplex virus infection: diagnostics and pathogenesis of genital tract"/>
  <result pre="J. Microbiol. Biotechnol.31453–460. 10.1007/s11274-015-1798-125604263 JohnstonC.CoreyL. (2015). Current concepts for genital" exact="herpes" post="simplex virus infection: diagnostics and pathogenesis of genital tract"/>
  <result pre="M.GibsonW.DennisP. A.AmbinderR. F. (2014). Nelfinavir inhibits maturation and export of" exact="herpes" post="simplex virus 1.J. Virol.885455–5461. 10.1128/JVI.03790-1324574416 KarunamoorthiK.JegajeevanramK.VijayalakshmiJ.MengistieE. (2013). Traditional medicinal"/>
  <result pre="al. (2017). Amenamevir, a novel helicase–primase inhibitor, for treatment of" exact="herpes" post="zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study.J. Dermatol.441219–1227."/>
  <result pre="R.LegerA. J. S.GuedonJ.-M. G.HendricksR. L. (2012). Herpes simplex virus and" exact="varicella" post="zoster virus, the house guests who never leave.Herpesviridae3:5. 10.1186/2042-4280-3-522691604"/>
  <result pre="J. S.GuedonJ.-M. G.HendricksR. L. (2012). Herpes simplex virus and varicella" exact="zoster" post="virus, the house guests who never leave.Herpesviridae3:5. 10.1186/2042-4280-3-522691604 KleymannG.FischerR.BetzU."/>
  <result pre="New helicase-primase inhibitors as drug candidates for the treatment of" exact="herpes" post="simplex disease.Nat. Med.8392–398. 10.1038/nm0402-39211927946 KroonS. (1990). Genital herpes–when and"/>
  <result pre="to treat.Semin. Dermatol.9133–140. 2202409 KukhanovaM. K.KorovinaA. N.KochetkovS. N. (2014). Human" exact="herpes" post="simplex virus: life cycle and development of inhibitors.Biochemistry791635–1652. 10.1134/S000629791413012425749169"/>
  <result pre="Efficacy of traditional herbal medicines in combination with acyclovir against" exact="herpes" post="simplex virus type 1 infection in vitro and in"/>
  <result pre="herbal medicines in combination with acyclovir against herpes simplex virus" exact="type 1" post="infection in vitro and in vivo.Antivir. Res.2719–37. 10.1016/0166-3542(94)00076-k7486956 KwantA.RosenthalK."/>
  <result pre="in combination with acyclovir against herpes simplex virus type 1" exact="infection" post="in vitro and in vivo.Antivir. Res.2719–37. 10.1016/0166-3542(94)00076-k7486956 KwantA.RosenthalK. L."/>
  <result pre="in vivo.Antivir. Res.2719–37. 10.1016/0166-3542(94)00076-k7486956 KwantA.RosenthalK. L. (2004). Intravaginal immunization with" exact="viral" post="subunit protein plus CpG oligodeoxynucleotides induces protective immunity against"/>
  <result pre="HSV-2.Vaccine223098–3104. 10.1016/j.vaccine.2004.01.05915297061 LaffertyW. E.CoombsR. W.BenedettiJ.CritchlowC.CoreyL. (1987). Recurrences after oral and" exact="genital herpes" post="simplex virus infection. Influence of site of infection and"/>
  <result pre="10.1016/j.vaccine.2004.01.05915297061 LaffertyW. E.CoombsR. W.BenedettiJ.CritchlowC.CoreyL. (1987). Recurrences after oral and genital" exact="herpes" post="simplex virus infection. Influence of site of infection and"/>
  <result pre="E.CoombsR. W.BenedettiJ.CritchlowC.CoreyL. (1987). Recurrences after oral and genital herpes simplex" exact="virus infection." post="Influence of site of infection and viral type.N. Engl."/>
  <result pre="and genital herpes simplex virus infection. Influence of site of" exact="infection" post="and viral type.N. Engl. J. Med.3161444–1449. 10.1056/nejm1987060431623043033506 LeaA. P.BrysonH."/>
  <result pre="herpes simplex virus infection. Influence of site of infection and" exact="viral" post="type.N. Engl. J. Med.3161444–1449. 10.1056/nejm1987060431623043033506 LeaA. P.BrysonH. M. (1996)."/>
  <result pre="to assess the efficacy of oral antiviral treatment to prevent" exact="genital herpes" post="outbreaks.J. Am. Acad. Dermatol.57238–246. 10.1016/j.jaad.2007.02.00817416440 LeeC. K.KimH. S.NamJ. R.LeeM."/>
  <result pre="assess the efficacy of oral antiviral treatment to prevent genital" exact="herpes" post="outbreaks.J. Am. Acad. Dermatol.57238–246. 10.1016/j.jaad.2007.02.00817416440 LeeC. K.KimH. S.NamJ. R.LeeM."/>
  <result pre="risk-benefit evaluation of aciclovir for the treatment and prophylaxis of" exact="herpes" post="simplex virus infections.Drug Saf.23131–142. 10.2165/00002018-200023020-0000410945375 LevendoskyK.MizeninaO.MartinelliE.Jean-PierreN.KizimaL.RodriguezA.et al. (2015). Griffithsin"/>
  <result pre="10.2165/00002018-200023020-0000410945375 LevendoskyK.MizeninaO.MartinelliE.Jean-PierreN.KizimaL.RodriguezA.et al. (2015). Griffithsin and carrageenan combination to target" exact="herpes" post="simplex virus 2 and human papillomavirus.Antimicrob. Agents Chemother.597290–7298. 10.1128/AAC.01816-1526369967"/>
  <result pre="10.1128/AAC.01816-1526369967 LeytonL.HottM.AcuñaF.CarocaJ.NuñezM.MartinC.et al. (2015). Nutraceutical activators of AMPK/Sirt1 axis inhibit" exact="viral" post="production and protect neurons from neurodegenerative events triggered during"/>
  <result pre="HSV-1 infection.Virus Res.20563–72. 10.1016/j.virusres.2015.05.01526031763 LiT.LiuL.WuH.ChenS.ZhuQ.GaoH.et al. (2017). Anti-herpes simplex virus" exact="type 1" post="activity of Houttuynoid A, a flavonoid from Houttuynia cordata"/>
  <result pre="host.Int. J. Mol. Sci.191–23. LiangT. M.FangY. W.ZhengJ. Y.ShaoC. L. (2018)." exact="Secondary" post="metabolites isolated from the gorgonian-derived fungus Aspergillus ruber and"/>
  <result pre="LipipunV.KurokawaM.SuttisriR.TaweechotipatrP.PramyothinP.HattoriM.et al. (2003). Efficacy of Thai medicinal plant extracts against" exact="herpes" post="simplex virus type 1 infection in vitro and in"/>
  <result pre="Efficacy of Thai medicinal plant extracts against herpes simplex virus" exact="type 1" post="infection in vitro and in vivo.Antiviral. Res.60175–180. 10.1016/s0166-3542(03)00152-914638393 LolisM."/>
  <result pre="Thai medicinal plant extracts against herpes simplex virus type 1" exact="infection" post="in vitro and in vivo.Antiviral. Res.60175–180. 10.1016/s0166-3542(03)00152-914638393 LolisM. S.GonzalezL.CohenP."/>
  <result pre="in vivo.Antiviral. Res.60175–180. 10.1016/s0166-3542(03)00152-914638393 LolisM. S.GonzalezL.CohenP. J.SchwartzR. A. (2016). Drug-resistant" exact="herpes" post="simplex virus in HIV infected patients.Acta Dermatovenerol. Croat.16204–208. LookerK."/>
  <result pre="(2008). An estimate of the global prevalence and incidence of" exact="herpes" post="simplex virus type 2 infection.Bull. World Heal. Organ.86805–812. 10.2471/blt.07.04612818949218"/>
  <result pre="of the global prevalence and incidence of herpes simplex virus" exact="type 2" post="infection.Bull. World Heal. Organ.86805–812. 10.2471/blt.07.04612818949218 LopesN.RayS.EspadaS. F.BomfimW. A.RayB.Faccin-GalhardiL. C.et"/>
  <result pre="Green seaweed Enteromorpha compressa (Chlorophyta, Ulvaceae) derived sulphated polysaccharides inhibit" exact="herpes" post="simplex virus.Int. J. Biol. Macromol.102605–612. 10.1016/j.ijbiomac.2017.04.04328431944 LuberA. D.FlahertyJ. F."/>
  <result pre="(2017). Antiviral activity of Eucalyptus camaldulensis leaves ethanolic extract on" exact="herpes" post="viruses infection.Int. J. Clin. Virol.1001–009. 10.29328/journal.ijcv.1001001 collab: Market Watch"/>
  <result pre="A preliminary evaluation of nelfinavir mesylate, an inhibitor of human" exact="immunodeficiency" post="virus (HIV)-1 Protease, to treat HIV infection.J. Infect. Dis.1771533–1540."/>
  <result pre="activity of Melissa officinalis L. extract on Herpes simplex virus" exact="type 2" post="replication.Nat. Prod. Res.221433–1440. 10.1080/1478641080207593919023806 McCarthyJ. P.BrowningW. D.TeerlinkC.VeitG. (2012). Treatment"/>
  <result pre="replication.Nat. Prod. Res.221433–1440. 10.1080/1478641080207593919023806 McCarthyJ. P.BrowningW. D.TeerlinkC.VeitG. (2012). Treatment of" exact="herpes" post="labialis: comparison of two OTC drugs and untreated controls.J."/>
  <result pre="al. (1998). Etiology of genital ulcers and prevalence of human" exact="immunodeficiency" post="virus coinfection in 10 US cities. The genital ulcer"/>
  <result pre="immunodeficiency virus coinfection in 10 US cities. The genital ulcer" exact="disease" post="surveillance group.J. Infect. Dis.1781795–1798. 10.1086/3145029815237 MindelA. (1991). Is it"/>
  <result pre="10.1086/3145029815237 MindelA. (1991). Is it meaningful to treat patients with" exact="recurrent" post="herpetic infections?Scand. J. Infect. Dis. Suppl.8027–32. 1803498 MondalD. (2007)."/>
  <result pre="MoomawM. D.CorneaP.RathbunR. C.WendelK. A. (2003). Review of antiviral therapy for" exact="herpes" post="labialis, genital herpes and herpes zoster.Expert. Rev. Anti Infect."/>
  <result pre="C.WendelK. A. (2003). Review of antiviral therapy for herpes labialis," exact="genital herpes" post="and herpes zoster.Expert. Rev. Anti Infect. Ther.1283–295. 10.1586/14787210.1.2.28315482124 MorfinF.ThouvenotD."/>
  <result pre="A. (2003). Review of antiviral therapy for herpes labialis, genital" exact="herpes" post="and herpes zoster.Expert. Rev. Anti Infect. Ther.1283–295. 10.1586/14787210.1.2.28315482124 MorfinF.ThouvenotD."/>
  <result pre="Review of antiviral therapy for herpes labialis, genital herpes and" exact="herpes" post="zoster.Expert. Rev. Anti Infect. Ther.1283–295. 10.1586/14787210.1.2.28315482124 MorfinF.ThouvenotD. (2003). Herpes"/>
  <result pre="10.1016/s1386-6532(02)00263-912589832 NixonB.StefanidouM.MesquitaP. M. M.FakiogluE.SegarraT.RohanL.et al. (2013). Griffithsin protects mice from" exact="genital herpes" post="by preventing cell-to-cell spread.J. Virol.876257–6269. 10.1128/JVI.00012-1323536670 OkbaM. M.El GedailyR."/>
  <result pre="NixonB.StefanidouM.MesquitaP. M. M.FakiogluE.SegarraT.RohanL.et al. (2013). Griffithsin protects mice from genital" exact="herpes" post="by preventing cell-to-cell spread.J. Virol.876257–6269. 10.1128/JVI.00012-1323536670 OkbaM. M.El GedailyR."/>
  <result pre="review of its long term utility in the management of" exact="genital herpes" post="simplex virus and cytomegalovirus infections.Drugs59839–863. 10.2165/00003495-200059040-0001310804039 PachecoP.SierraJ.Schmeda-HirschmanG.PotterC. W.JonesB. M.MoshrefM.et"/>
  <result pre="of its long term utility in the management of genital" exact="herpes" post="simplex virus and cytomegalovirus infections.Drugs59839–863. 10.2165/00003495-200059040-0001310804039 PachecoP.SierraJ.Schmeda-HirschmanG.PotterC. W.JonesB. M.MoshrefM.et"/>
  <result pre="virus (HSV-1) in vitro and its therapeutic efficacy against HSV-1" exact="Infection" post="in Mice.Biol. Pharm. Bull.282258–2262. 10.1248/bpb.28.225816327161 PatickA. K.MoH.MarkowitzM.AppeltK.WuB.MusickL.et al. (1996)."/>
  <result pre="resistance studies of AG1343, an orally bioavailable inhibitor of human" exact="immunodeficiency" post="virus protease.Antimicrob. Agents Chemother.40292–297. 10.1128/aac.40.2.2928834868 Paz-BaileyG.RamaswamyM.HawkesS. J.GerettiA. M. (2008)."/>
  <result pre="PernaJ. J.MannixM. L.RooneyJ. F.NotkinsA. L.StrausS. E. (1987). Reactivation of latent" exact="herpes" post="simplex virus infection by ultraviolet light: a human model.J."/>
  <result pre="L.RooneyJ. F.NotkinsA. L.StrausS. E. (1987). Reactivation of latent herpes simplex" exact="virus infection" post="by ultraviolet light: a human model.J. Am. Acad. Dermatol.17473–478."/>
  <result pre="F.NotkinsA. L.StrausS. E. (1987). Reactivation of latent herpes simplex virus" exact="infection" post="by ultraviolet light: a human model.J. Am. Acad. Dermatol.17473–478."/>
  <result pre="anti-herpes simplex virus activity of n-docosanol includes inhibition of the" exact="viral" post="entry process.Antivir. Res.4085–94. 10.1016/s0166-3542(98)00048-59864049 PradeepP.ManjuV.AhsanM. F. (2019). &quot;Antiviral potency"/>
  <result pre="R.QuenelleD. C. (2011). CMX001 potentiates the efficacy of acyclovir in" exact="herpes" post="simplex virus infections.Antimicrob. Agents Chemother.554728–4734. 10.1128/AAC.00545-1121788472 PujolC. A.RayS.RayB.DamonteE. B."/>
  <result pre="C.LampertB.CollinsD. J.RiceT. L.PainterG. R.KernE. R. (2010). Efficacy of CMX001 against" exact="herpes" post="simplex virus infections in mice and correlations with drug"/>
  <result pre="R.KernE. R. (2010). Efficacy of CMX001 against herpes simplex virus" exact="infections" post="in mice and correlations with drug distribution studies.J. Infect."/>
  <result pre="drug distribution studies.J. Infect. Dis.2021492–1499. 10.1086/65671720923374 RamchandaniM.KongM.TronsteinE.SelkeS.MikhaylovaA.MagaretA.et al. (2017). Oral" exact="mucosa" post="of healthy adults.Sex. Trans. Dis.43756–760. RandK. H.HoonE. F.MasseyJ. K.JohnsonJ."/>
  <result pre="H.HoonE. F.MasseyJ. K.JohnsonJ. H. (1990). Daily stress and recurrence of" exact="genital herpes" post="simplex.Arch. Intern. Med.1501889–1893. 10.1001/archinte.150.9.18892393320 RattanathongkomA.LeeJ.-B.HayashiK.SripanidkulchaiB.-O.KanchanapoomT.HayashiT. (2009). Evaluation of Chikusetsusaponin"/>
  <result pre="F.MasseyJ. K.JohnsonJ. H. (1990). Daily stress and recurrence of genital" exact="herpes" post="simplex.Arch. Intern. Med.1501889–1893. 10.1001/archinte.150.9.18892393320 RattanathongkomA.LeeJ.-B.HayashiK.SripanidkulchaiB.-O.KanchanapoomT.HayashiT. (2009). Evaluation of Chikusetsusaponin"/>
  <result pre="Chikusetsusaponin IVa isolated from Alternanthera philoxeroides for its potency against" exact="viral" post="replication.Planta Med.75829–835. 10.1055/s-0029-118543619277947 ReusserP. (1996). Herpesvirus resistance to antiviral"/>
  <result pre="Infect.33235–248. 10.1016/s0195-6701(96)90010-98864937 RibeiroM.RobainaM.MendesG.SilvaT.GestinariL.PamplonaO.et al. (2012). Antiviral activity of extracts from" exact="Brazilian" post="seaweeds against herpes simplex virus.Rev. Bras. Farmacogn.22714–723. 10.3390/molecules1805576123681060 RonerM."/>
  <result pre="al. (2012). Antiviral activity of extracts from Brazilian seaweeds against" exact="herpes" post="simplex virus.Rev. Bras. Farmacogn.22714–723. 10.3390/molecules1805576123681060 RonerM. R.SprayberryJ.SpinksM.DhanjiS. (2007). Antiviral"/>
  <result pre="saponaria Molina).J. Gen. Virol.88275–285. 10.1099/vir.0.82321-017170461 RoozbahaniM.HammersmithK. M. (2018). Management of" exact="herpes" post="simplex virus epithelial keratitis.Curr. Opin. Ophthalmol.29360–364. 10.1097/ICU.000000000000048329697435 RowleyD. C.KellyS.KauffmanC."/>
  <result pre="Virol.88275–285. 10.1099/vir.0.82321-017170461 RoozbahaniM.HammersmithK. M. (2018). Management of herpes simplex virus" exact="epithelial" post="keratitis.Curr. Opin. Ophthalmol.29360–364. 10.1097/ICU.000000000000048329697435 RowleyD. C.KellyS.KauffmanC. A.JensenP. R.FenicalW. (2003)."/>
  <result pre="al. (2001). Clinical efficacy of topical docosanol 10% cream for" exact="herpes" post="simplex labialis: a multicenter, randomized, placebo-controlled trial.J. Am. Acad."/>
  <result pre="Phycol.24731–741. 10.1007/s10811-011-9692-1 SariskyR. T.BaconT.BoonR.LockeL.NguyenT. T.LearyJ.et al. (2002). Penciclovir susceptibilities of" exact="herpes" post="simplex virus isolates from patients using penciclovir cream for"/>
  <result pre="virus isolates from patients using penciclovir cream for treatment of" exact="recurrent" post="herpes labialis.Antimicrob. Agents Chemother.462848–2853. 10.1128/aac.46.9.2848-2853.200212183237 SariskyR. T.BaconT. H.BoonR. J.DuffyK."/>
  <result pre="isolates from patients using penciclovir cream for treatment of recurrent" exact="herpes" post="labialis.Antimicrob. Agents Chemother.462848–2853. 10.1128/aac.46.9.2848-2853.200212183237 SariskyR. T.BaconT. H.BoonR. J.DuffyK. E.EsserK."/>
  <result pre="al. (2003). Profiling penciclovir susceptibility and prevalence of resistance of" exact="herpes" post="simplex virus isolates across eleven clinical trials.Arch. Virol.1481757–1769. 10.1007/s00705-003-0124-714505088"/>
  <result pre="L.LeeF. K.NahmiasA. J.et al. (2004). National seroprevalence and trends in" exact="herpes" post="simplex virus type 1 in the United States, 1976-1994.Sex"/>
  <result pre="al. (2004). National seroprevalence and trends in herpes simplex virus" exact="type 1" post="in the United States, 1976-1994.Sex Transm. Dis.31753–760. 10.1097/01.olq.0000145852.43262.c315608591 SchnitzlerP.SchönK.ReichlingJ."/>
  <result pre="activity of Australian tea tree oil and eucalyptus oil against" exact="herpes" post="simplex virus in cell culture.Pharmazie56343–347. 11338678 SchusterA. K.HarderB. C.SchlichtenbredeF."/>
  <result pre="C.JarczokM. N.TesarzJ. (2016). Valacyclovir versus acyclovir for the treatment of" exact="herpes zoster" post="ophthalmicus in immunocompetent patients.Cochrane Database Syst. Rev.1:CD011503. SebeiK.SakouhiF.HerchiW.KhoujaM. L.BoukhchinaS."/>
  <result pre="N.TesarzJ. (2016). Valacyclovir versus acyclovir for the treatment of herpes" exact="zoster" post="ophthalmicus in immunocompetent patients.Cochrane Database Syst. Rev.1:CD011503. SebeiK.SakouhiF.HerchiW.KhoujaM. L.BoukhchinaS."/>
  <result pre="(2019). Kanuka honey versus aciclovir for the topical treatment of" exact="herpes" post="simplex labialis: a randomised controlled trial.BMJ Open9:e026201. 10.1136/bmjopen-2018-02620131092654 ShaikhB."/>
  <result pre="10.1093/ecam/neh08815937553 SimpsonD.Lyseng-WilliamsonK. A. (2006). Famciclovir– review of its use in" exact="herpes zoster" post="and genital and orolabial herpes.Drugs662397–2416. 10.2165/00003495-200666180-0001617181386 SmeeD.MartinJ.VerheydenJ.MatthewsT. (1983). Anti-Herpesvirus"/>
  <result pre="SimpsonD.Lyseng-WilliamsonK. A. (2006). Famciclovir– review of its use in herpes" exact="zoster" post="and genital and orolabial herpes.Drugs662397–2416. 10.2165/00003495-200666180-0001617181386 SmeeD.MartinJ.VerheydenJ.MatthewsT. (1983). Anti-Herpesvirus"/>
  <result pre="Agents Chemother.23676–682. 10.1128/aac.23.5.6766307132 SmithJ. S.RobinsonN. J. (2002). Age-specific prevalence of" exact="infection" post="with herpes simplex virus types 2 and 1: a"/>
  <result pre="10.1128/aac.23.5.6766307132 SmithJ. S.RobinsonN. J. (2002). Age-specific prevalence of infection with" exact="herpes" post="simplex virus types 2 and 1: a global review.J."/>
  <result pre="glycolipids from the marine algae Osmundaria obtusiloba isolated from Southeastern" exact="Brazilian" post="coast.Mar. Drugs.10918–931. 10.3390/md1004091822690151 SouzaT. M. L.AbrantesJ. L.EpifanioR. D. A.FontesC."/>
  <result pre="isolated from the sponge Aaptos aaptos impairs Herpes simplex virus" exact="type 1" post="penetration and immediate-early protein synthesis.Planta Med.73200–205. 10.1055/s-2007-96710917285480 SpruanceS. L."/>
  <result pre="Med.73200–205. 10.1055/s-2007-96710917285480 SpruanceS. L. (1993). Prophylactic chemotherapy with acyclovir for" exact="recurrent" post="herpes simplex labialis.J. Med. Virol.41(1 Suppl), 27–32. 10.1002/jmv.18904105078245889 SpruanceS."/>
  <result pre="10.1055/s-2007-96710917285480 SpruanceS. L. (1993). Prophylactic chemotherapy with acyclovir for recurrent" exact="herpes" post="simplex labialis.J. Med. Virol.41(1 Suppl), 27–32. 10.1002/jmv.18904105078245889 SpruanceS. L.OverallJ."/>
  <result pre="L.OverallJ. C.Jr.KernE. R.KruegerG. G.PliamV.et al. (1977). The natural history of" exact="recurrent" post="herpes simplex labialis: implications for antiviral therapy.N. Engl. J."/>
  <result pre="C.Jr.KernE. R.KruegerG. G.PliamV.et al. (1977). The natural history of recurrent" exact="herpes" post="simplex labialis: implications for antiviral therapy.N. Engl. J. Med.29769–75."/>
  <result pre="10.1056/nejm197707142970201194157 SpruanceS. L.StewartJ. C.RoweN. H.McKeoughM. B.WenerstromG.FreemanD. J. (1990). Treatment of" exact="recurrent" post="herpes simplex labialis with oral acyclovir.J. Infect. Dis.161185–190. 2153735"/>
  <result pre="SpruanceS. L.StewartJ. C.RoweN. H.McKeoughM. B.WenerstromG.FreemanD. J. (1990). Treatment of recurrent" exact="herpes" post="simplex labialis with oral acyclovir.J. Infect. Dis.161185–190. 2153735 StevensJ."/>
  <result pre="oral acyclovir.J. Infect. Dis.161185–190. 2153735 StevensJ. G.CookM. L. (1971). Latent" exact="herpes" post="simplex virus in spinal ganglia of mice.Science173843–845. 10.1126/science.173.3999.8434328483 StrandA.BöttigerD.GeverL."/>
  <result pre="combination acyclovir 5% and hydrocortisone 1% cream in adolescents with" exact="recurrent" post="herpes simplex labialis.Pediatr. Dermatol.29105–110. 10.1111/j.1525-1470.2011.01570.x22004219 StranskaR.SchuurmanR.NienhuisE.GoedegebuureI. W.PolmanM.WeelJ. F.et al."/>
  <result pre="acyclovir 5% and hydrocortisone 1% cream in adolescents with recurrent" exact="herpes" post="simplex labialis.Pediatr. Dermatol.29105–110. 10.1111/j.1525-1470.2011.01570.x22004219 StranskaR.SchuurmanR.NienhuisE.GoedegebuureI. W.PolmanM.WeelJ. F.et al. (2005)."/>
  <result pre="Dermatol.29105–110. 10.1111/j.1525-1470.2011.01570.x22004219 StranskaR.SchuurmanR.NienhuisE.GoedegebuureI. W.PolmanM.WeelJ. F.et al. (2005). Survey of acyclovir-resistant" exact="herpes" post="simplex virus in the Netherlands: prevalence and characterization.J. Clin."/>
  <result pre="10.1016/j.carbpol.2014.08.06825439876 TreisterN. S.WooS. B. (2010). Topical n-docosanol for management of" exact="recurrent" post="herpes labialis.Expert Opin. Pharmacother.11853–860. 10.1517/1465656100369184720210688 van DiemenF. R.KruseE. M.HooykaasM."/>
  <result pre="TreisterN. S.WooS. B. (2010). Topical n-docosanol for management of recurrent" exact="herpes" post="labialis.Expert Opin. Pharmacother.11853–860. 10.1517/1465656100369184720210688 van DiemenF. R.KruseE. M.HooykaasM. J."/>
  <result pre="Biol.53682–688. 10.3109/13880209.2014.93694425431185 Vere HodgeR. A.FieldH. J. (2013). &quot;Antiviral agents for" exact="herpes" post="simplex virus,&quot; in Advances in Pharmacology, 1st Edn, Vol."/>
  <result pre="infection.N. Engl. J. Med.370201–210. 10.1056/NEJMoa130115024428466 WhitleyR.DavisE. A.SuppapanyaN. (2007). Incidence of" exact="neonatal" post="herpes simplex virus infections in a managed-care population.Sex Transm."/>
  <result pre="Engl. J. Med.370201–210. 10.1056/NEJMoa130115024428466 WhitleyR.DavisE. A.SuppapanyaN. (2007). Incidence of neonatal" exact="herpes" post="simplex virus infections in a managed-care population.Sex Transm. Dis.34704–708."/>
  <result pre="10.1056/NEJMoa130115024428466 WhitleyR.DavisE. A.SuppapanyaN. (2007). Incidence of neonatal herpes simplex virus" exact="infections" post="in a managed-care population.Sex Transm. Dis.34704–708. 10.1097/01.olq.0000258432.33412.e217413535 collab: WHO"/>
  <result pre="in a managed-care population.Sex Transm. Dis.34704–708. 10.1097/01.olq.0000258432.33412.e217413535 collab: WHO (2000)." exact="General" post="Guidelines for Methodologies on Research and Evaluation of Traditional"/>
  <result pre="WilhelmusK. R. (2015). Antiviral treatment and other therapeutic interventions for" exact="herpes" post="simplex virus epithelial keratitis.Cochrane Database Syst. Rev.20151–231. WolfK. J."/>
  <result pre="Antiviral treatment and other therapeutic interventions for herpes simplex virus" exact="epithelial" post="keratitis.Cochrane Database Syst. Rev.20151–231. WolfK. J. (2017). Safety and"/>
  <result pre="final rule.Fed. Regist.8260474–60503. 29260839 WooS. B.ChallacombeS. J. (2007). Management of" exact="recurrent" post="oral herpes simplex infections.Oral. Surg. Oral. Med. Oral. Pathol."/>
  <result pre="Regist.8260474–60503. 29260839 WooS. B.ChallacombeS. J. (2007). Management of recurrent oral" exact="herpes" post="simplex infections.Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol."/>
  <result pre="Radiol. Endod.103(Suppl. 12), e1–e18. WylesD. L.PatelA.MadingerN.BessesenM.KrauseP. R.WeinbergA. (2005). Development of" exact="herpes" post="simplex virus disease in patients who are receiving cidofovir.Clin."/>
  <result pre="e1–e18. WylesD. L.PatelA.MadingerN.BessesenM.KrauseP. R.WeinbergA. (2005). Development of herpes simplex virus" exact="disease" post="in patients who are receiving cidofovir.Clin. Infect. Dis.41676–680. 10.1086/43247716080090"/>
  <result pre="Infect. Dis.41676–680. 10.1086/43247716080090 XuF.MarkowitzL. E.GottliebS. L.BermanS. M. (2007). Seroprevalence of" exact="herpes" post="simplex virus types 1 and 2 in pregnant women"/>
  <result pre="XuF.MarkowitzL. E.GottliebS. L.BermanS. M. (2007). Seroprevalence of herpes simplex virus" exact="types 1 and 2" post="in pregnant women in the United States.Am. J. Obs."/>
  <result pre="a brown alga (Cystoseira myrica) from the Persian Gulf against" exact="herpes" post="simplex virus type 1.Afr. J. Biotechnol.62511–2514. 10.5897/ajb2007.000-2399 ZiyaeyanM.AlborziA.JaponiA.KadivarM.DavarpanahM. A.PourabbasB.et"/>
  <result pre="J. Biotechnol.62511–2514. 10.5897/ajb2007.000-2399 ZiyaeyanM.AlborziA.JaponiA.KadivarM.DavarpanahM. A.PourabbasB.et al. (2007). Frequency of acyclovir-resistant" exact="herpes" post="simplex viruses isolated from the general immunocompetent population and"/>
  <result pre="viruses isolated from the general immunocompetent population and patients with" exact="acquired" post="immunodeficiency syndrome.Int. J. Dermatol.461263–1266. 10.1111/j.1365-4632.2007.03449.x18173520"/>
  <result pre="isolated from the general immunocompetent population and patients with acquired" exact="immunodeficiency" post="syndrome.Int. J. Dermatol.461263–1266. 10.1111/j.1365-4632.2007.03449.x18173520"/>
 </snippets>
</snippetsTree>
